Crystalline forms of 2,2,2-trifluoro-N-[(1R,2S)-1-{[1-(4-fluorophenyl)-1H- indazol-5-yl]oxy}-1-(3-methoxyphenyl)-2-propanyl]acetamide (AZD-5423)

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 9, 2013, Pages 1239-1245

  Norman, Peter ^a  

^a NORMAN CONSULTING   (United Kingdom)

Author keywords

Asthma; Chronic obstructive pulmonary disease; Crystalline form; Glucocorticoid receptor; Inhaled therapy; Steroid; Transrepression

Indexed keywords

2,2,2 TRIFLUORO N [1 [[1 (4 FLUOROPHENYL) 1H INDAZOL 5 YL]OXY] 1 (3 METHOXYPHENYL) 2 PROPANYL]ACETAMIDE; 4 (2,3 DIHYDROBENZOFURAN 7 YL) 2 HYDROXY 3,3 DIMETHYL N (4 METHYL 1 OXO 2,3 BENZOXAZIN 6 YL) 2 TRIFLUOROMETHYLBUTANAMIDE; AZD 5423; BI 54903; BMS 776532; BMS 791826; GLUCOCORTICOID RECEPTOR ANTAGONIST; MAPRACORAT; PF 04171327; TRIFLUOROACETAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE EFFECTIVENESS; DRUG ABSORPTION; DRUG SYNTHESIS; HUMAN; PATENT; PHASE 2 CLINICAL TRIAL (TOPIC);

ACETAMIDES; ADMINISTRATION, INHALATION; ANIMALS; ASTHMA; CRYSTALLIZATION; HUMANS; INDAZOLES; PATENTS AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, GLUCOCORTICOID;

EID: 84882807314     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.820706     Document Type: Article

References (31)

1. Buckbinder L, Robinson RP. The glucocorticoid receptor: Molecular mechanism and new therapeutic opportunities. Curr Drug Targets Inflamm Allergy 2002;1(2):127-36
2. Chung KF, Caramori G, Adcock IM. Inhaled corticosteroids as combination therapy with beta-Adrenergic agonists in airways disease: Present and future. Eur J Clin Pharmacol 2009;65(9):853-71
3. Barnes PJ. Glucocorticosteroids: Current and future directions. Br J Pharmacol 2011;163(1):29-43
4. Adcock IM, Caramori G, Ito K. New insights into the molecular mechanisms of corticosteroids actions. Curr Drug Targets 2006;7(6):649-60
5. De Bosscher K, Haegeman G, Elewaut D. Targeting inflammation using selective glucocorticoid receptor modulators. Curr Opin Pharmacol 2010;10(4):497-504
6. Biggadike K, Bledsoe RK, Hassell AM, et al. X-ray crystal structure of the novel enhanced-Affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. J Med Chem 2008;51(12):3349-52
7. Biggadike K, Bledsoe RK, Coe DM, et al. Design and x-ray crystal structures of high-potency nonsteroidal glucocorticoid agonists exploiting a novel binding site on the receptor. Proc Natl Acad Sci USA 2009;106(43):18114-19
8. Diallo H, Angell DC, Barnett HA, et al. Discovery of a potent series of non-steroidal non alpha-trifluoromethyl carbinol glucocorticoid receptor agonists with reduced lipophilicity. Bioorg Med Chem Lett 2011;21(4):1126-33
9. Kuzmich D, Kirrane T, Proudfoot J, et al. Identification of dissociated non-steroidal glucocorticoid receptor agonists. Bioorg Med Chem Lett 2007;17(18):5025-31
10. Norman P. Boehringer Ingleheim's selective glucocorticoid receptor agonist development candidate: Evaluation of WO2010141331, WO2010141332 and WO2010141333. Expert Opin Ther Pat 2011;21(7):1137-42
11. Jaroch S, Berger M, Huwe C, et al. Discovery of quinolines as selective glucocorticoid receptor agonists. Bioorg Med Chem Lett 2010;20(19):5835-8
12. Schäcke H, Zollner TM, Docke WD, et al. Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Br J Pharmacol 2009;158(4):1088-103
13. Vollmer TR, Stockhausen A, Zhang JZ. Anti-inflammatory effects of mapracorat, a novel selective glucocorticoid receptor agonist, is partially mediated by MAP kinase phosphatase-1 (MKP-1). J Biol Chem 2012;287(42):35212-21
14. Weinstein DS, Gong H, Doweyko AM, et al. Azaxanthene based selective glucocorticoid receptor modulators: Design, synthesis, and pharmacological evaluation of (S)-4-(5-(1-((1,3,4- thiadiazol-2-yl)amino)-2-methyl-1- oxopropan-2-yl)-5H-chromeno[2,3-b] pyridin-2-yl)-2-fluoro-N, N-dimethylbenzamide (BMS-776532) and its methylene homologue (BMS- 791826). J Med Chem 2011;54(20):7318-33
15. van Lierop MJ, Alkema W, Laskewitz AJ, et al. Org 214007-0: A novel non-steroidal selective glucocorticoid receptor modulator with full anti-inflammatory properties and improved therapeutic index. PLoS One 2012;7(11):e48385
16. Stock T, Fleishaker D, Mukherjee A, et al. Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of a Selective Glucocorticoid Receptor Modulator (SGRM) in Healthy Volunteers [abstract]. Arthritis Rheum 2009;60(Suppl 10):420
17. Pfizer Products, Inc. Tricyclic compounds and their use as glucocorticoid receptor modulators. WO2008093227; 2008
18. Schering AG. Nonsteroidal antiinflammatories. WO0032584; 2000
19. AstraZeneca AB. Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases. WO2006046916; 2006
20. Drahl C. AZD5423, for chronic obstructive pulmonary disease. Chem Eng News 2013;91(16):14-15
21. Astra Zeneca AB, Bayer Schering Pharma AG. Indazolyl ester and amide derivatives for the treatment of glucocorticoid receptor mediated disorders. WO2008076048; 2008
22. Giembycz MA, Kaur M, Leigh R, Newton R. A Holy Grail of asthma management: Toward understanding how long-Acting beta(2)-Adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Br J Pharmacol 2008;153(6):1090-104
23. AstraZeneca AB, Bayer Schering Pharma AG. Combination of (a) glucocorticoid receptor modulator and (b) a b2-Agonist. WO2009142568; 2009
24. AstraZeneca AB. A combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist. WO2010008341; 2010
25. AstraZeneca AB, Bayer Pharma AG. Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases. WO2011061527; 2011
26. AstraZeneca AB. Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders. WO2013001294; 2013
27. Hannson T, Berger M, Dahmen J, et al. Discovery of AZD5423, a potent and selective non-steroidal glucocorticoid receptor modulator for the inhaled treatment of respiratory diseases. 245th ACS Meeting; 2013. MEDI278
28. O'Byrne PM, Gauvreau GM, Boulet LP, et al. Effect Of An Inhaled Selective Glucocorticoid Receptor Modulator (AZD5423) On Allergen-Induced Airway Responses And Airway Inflammation. Am J Respir Crit Care Med 2013;187:A2614 Available from: Http://clinicaltrials.gov/ ct2/results?term=bi54903&Search= Search
29. Norman P. New Combinations for asthma and COPD, in inhalation delivery. Scrip Business Insights 2013;In press
30. Norman P. New dual acting bronchodilator treatments for COPD, muscarinic antagonists and beta 2 agonists in combination or combined into a single molecule. Exp Opin Investig Drugs, submitted
31. AstraZeneca plc. AstraZeneca to acquire Pearl Therapeutics to strengthen respiratory portfolio, Press Release, 10 June 2013